Prolonged survival after invasive aspergillosis: A single-institution review of 11 cases

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 4, 2003, Pages 286-291

  Wright, Jessica A ^a,b   Bradfield, Scott M ^a   Park, Julie R ^a   Hawkins, Douglas S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Invasive aspergillosis; Malignancy; Pediatrics

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EARLY DIAGNOSIS; FOLLOW UP; GRANULOCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; LUNG ASPERGILLOSIS; LUNG BIOPSY; LUNG LOBECTOMY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THORACOSCOPY; THORACOTOMY;

ADOLESCENT; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; BIOPSY; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; LEUKEMIA; LUNG DISEASES, FUNGAL; MALE; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS;

EID: 0037397402     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200304000-00004     Document Type: Article

References (36)

1. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-200.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26:781-803.
3. Ritter J, Roos N. Special aspects related to invasive fungal infections in children with cancer. Bailliere's Clin Infect Dis 1995;2:179-204.
4. Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999;29:453-7.
5. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
6. Denning D, Marinus A, Cohen J. et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J Infect 1998;37:173-80.
7. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 2000;79:250-60.
8. Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000;31:859-68.
9. Mahoney DH, Steuber CP, Starling KA. et al. An outbreak of aspergillosis in children with acute leukemia. J Pediatr 1979;95:70-2.
10. Shamberger RC, Weinstein HJ, Grier HE, et al. The surgical management of fungal pulmonary infections in children with acute myelogenous leukemia. J Pediatr Surg 1985;20:840-4.
11. Bomelburg T, Roos N, von Lengerke JH. et al. Invasive aspergillosis complicating induction chemotherapy of childhood leukemia. Eur J Pediatr 1992;151: 485-7.
12. Lupinetti FM, Behrendt DM, Giller RH, et al. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J Thorac Cardiovasc Surg 1992;104:684-7.
13. Suc A, Bremont F, Rubie H, et al. Successful combination of Amphotericin therapy and surgical resection for fungal necrotizing pneumonia in a child receiving chemotherapy for leukemia. Pediatr Pulmonol 1997;23:386-8.
14. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280-6.
15. Ringden O, Tollemar J, Dahliof G, et al. High cure rate of invasive fungal infections in immunocompromised children using Ambisome. Transplant Proc 1994;26:175-7.
16. Walmsley S, Devi S, King S, et al. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediat Infect Disease J 1993;12:673-82.
17. Bomelburg T, Roos N, Fegeler W, et al. Invasive aspergillosis during chemotherapy in children. Hamatologie und Bluttransfusion 1994;36:778-81.
18. Abassi S, Shenep JL, Hughes WT, et al. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999;29:1210-9.
19. Groll, AH, Kurz M, Schneider W, et al. Five-year survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 1999;42:431-42.
20. George D, Miniter P, Andriole V. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996;40:86-91.
21. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34.
22. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71.
23. Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997;41:1835-6.
24. Rubin MA, Carroll KC, Cahill BC. Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002; 34:1160-1.
25. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
26. Walsh TJ, Gonzalez C, Lyman CA, et al. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatri Infect Dis 1996;11: 187-290.
27. Salerno CT, Ouyang DW, Pederson TS, et al. Surgical therapy for pulmonary aspergillosis in immunocompromised patients. Ann Thorac Surg 1998;65: 1415-9.
28. Baron O, Guillaume B, Moreau P, et al. Aggressive surgical management in localized pulmonary mycotic and nonmycotic infections for neutropenic patients with acute leukemia: report of eighteen cases. J Thorac Cardiovasc Surg 1998; 115:63-9.
29. Reichenberger F, Habicht J, Kaim A, et al. Lung resection for invasive pulmonary aspergillosis in neutropenic patients with hematologic diseases. Am J Respir Crit Care Med 1998;885-90.
30. Bernard A, Caillot D, Couaillier J, et al. Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann Thorac Surg 1997;64: 1441-7.
31. Pidhorecky I, Urschel J, Anderson T. Resection of pulmonary aspergillosis in immunocompromised patients. Ann Surg Oncol 2000;7:312-7.
32. Wong K, Waters CM, Walesby RK. Surgical management of invasive pulmonary aspergillosis in immunocompromised patients. Eur J Cardiothorac Surg 1992;6:138-43.
33. Robinson LA, Reed EC, Galbraith TA, et al. Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. J Thorac Cardiovasc Surg 1995;109:1182-97.
34. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;6:365-76.
35. Denning DW, Tucker RM, Hanson LH, et al. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989;86:791-800.
36. Maschmeyer, G. New antifungal agents: treatment standards are beginning to grow old. J Antimicrob Chemotherapy 2002;49:239-41.